AC Immune (NASDAQ:ACIU) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

AC Immune SA (NASDAQ:ACIU)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.51 and traded as low as $2.87. AC Immune shares last traded at $2.94, with a volume of 79,680 shares changing hands.

Analyst Upgrades and Downgrades

ACIU has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Trading Up 0.7 %

The firm’s 50-day moving average price is $3.17 and its 200 day moving average price is $3.51. The company has a market cap of $290.88 million, a price-to-earnings ratio of -6.39 and a beta of 1.26.

Institutional Investors Weigh In On AC Immune

A number of large investors have recently bought and sold shares of the stock. Vanguard Capital Wealth Advisors acquired a new position in shares of AC Immune during the second quarter valued at about $56,000. China Universal Asset Management Co. Ltd. increased its position in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in AC Immune during the 2nd quarter worth approximately $218,000. Geode Capital Management LLC boosted its holdings in AC Immune by 6.4% in the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock worth $220,000 after acquiring an additional 3,499 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in AC Immune by 294.7% in the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after acquiring an additional 328,312 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.